Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
| ▸ | MIF | P14174 | 3/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19638433 | 0.79 | SLC6A12 (0.39) | — | |
| SCHEMBL24898991 | 0.76 | — | — | |
| SCHEMBL1863234 | 0.74 | — | — | |
| SCHEMBL19651889 | 0.71 | CYP3A4 (0.31) | HSD17B10 | |
| SCHEMBL1301602 | 0.71 | CYP3A4 (0.31) | HSD17B10 | |
| SCHEMBL1301603 | 0.71 | CYP3A4 (0.31) | HSD17B10 | |
| SCHEMBL24942763 | 0.71 | CYP3A4 (0.31) | HSD17B10 | |
| SCHEMBL1301601 | 0.71 | CYP3A4 (0.31) | HSD17B10 | |
| SCHEMBL22608006 | 0.71 | CYP3A4 (0.31) | HSD17B10 | |
| SCHEMBL24942196 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107417505-B | Preparation method of alpha-halogenated tetramethyl cyclohexanone and (2,3,4, 4-tetramethylcyclopentyl) methyl carboxylic ester | 信越化学工业株式会社 | 2021-04-06 | — | — | CN | disclosed |
| CN-107417505-B | Preparation method of alpha-halogenated tetramethyl cyclohexanone and (2,3,4, 4-tetramethylcyclopentyl) methyl carboxylic ester | 信越化学工业株式会社 | 2021-04-06 | — | — | CN | disclosed |
| US-9919994-B2 | Alpha-halotetramethycyclohexanone, a method for the preparation thereof, and a method for the preparation of a (2,3,4,4-tetramethylcyclopentyl)methy carboxylate compound | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2018-03-20 | — | — | US | disclosed |
| US-9919994-B2 | Alpha-halotetramethycyclohexanone, a method for the preparation thereof, and a method for the preparation of a (2,3,4,4-tetramethylcyclopentyl)methy carboxylate compound | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2018-03-20 | — | — | US | disclosed |
| US-20170342013-A1 | ALPHA-HALOTETRAMETHYCYCLOHEXANONE, A METHOD FOR THE PREPARATION THEREOF, AND A METHOD FOR THE PREPARATION OF A (2,3,4,4-TETRAMETHYLCYCLOPENTYL)METHY CARBOXYLATE COMPOUND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-11-30 | — | — | US | disclosed |
| EP-3248959-A2 | ALPHA HALOTETRAMETHYLCYCLOHEXANONE, A METHOD FOR THE PREPARATION THEREOF, AND A METHOD FOR THE PREPARATION OF A (2,3,4,4-TETRAMETHYLCYCLOPENTYL) METHYL CARBOXYLATE COMPOUND | Shin-Etsu Chemical Co., Ltd. (JP) | 2017-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342013-A1 | ALPHA-HALOTETRAMETHYCYCLOHEXANONE, A METHOD FOR THE PREPARATION THEREOF, AND A METHOD FOR THE PREPARATION OF A (2,3,4,4-TETRAMETHYLCYCLOPENTYL)METHY CARBOXYLATE COMPOUND | PTMS, FOSB, PTMA | TSHR 2225/4885HSD17B10 781/4885BRD4 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.